Stock LLM Wiki

報告_UBS_義隆2458_3Q26_20261105

更新 2026-11-07

PDF 原檔:報告_UBS_義隆2458_3Q26_20261105_original.pdf

圖片清單(已驗證 2026-11-07)

檔名 分類 親眼所見內容
報告_UBS_義隆2458_3Q26_20261105_001.png(37KB,<40KB 仍親讀) 真資料圖(股價/本益比,財務類不嵌 lib) ELAN 股價(2014-10 至 2026-10)與 NTM P/E 曲線,平均 13x、±1 標準差 10x/16x
報告_UBS_義隆2458_3Q26_20261105_002.png 真資料圖(股價/外資持股,財務類不嵌 lib) 2014–2026 股價面積圖與 FINI 外資持股比率(右軸)曲線;2019 前後外資持股高點,2026 約 15–20% 區間回升
報告_UBS_義隆2458_3Q26_20261105_003.png 真資料圖(目標價沿革,披露頁,財務類不嵌 lib) 2023-08 至 2026-10 股價與目標價階梯線,下方為 Buy/No Rating 評等區間

原始內容

First Read

Elan Microelectronics

Q426E likely to be the near-term trough

Q326 earnings below on softer NB demand environment

Elan's Q326 EPS of N $0.58 (net profit N $168mn) was below UBSe/street of N $1.29/1.71, as a result of lower revenue amid weaker NB demand environment. Q326 revenue was already reported at N $2.2bn (-31% QoQ), below UBSe/street of N $2.4/2.8 bn as NB brand customers further reduced their orders from late-Aug on softer end-demand after retail price hike and higher component inventories. GM was down 2.7ppts QoQ to 44.7% on less favourable mix, directionally in-line with UBSe of ~2ppt QoQ decline. It booked non-op loss of N $100mn, vs N $294mn gain in Q226, mainly due to unrealized loss on financial assets. Despite softer earnings, Elan remains committed on its high dividend yield policy and is considering to raise its payout.

Near-term demand remains m ted b t Q426E likely to be the tro gh

Elan is restricted from providing Q4 financial guidance given the accumulated non-op gain in past four quarters exceeded 10% of the net profit. With October sales reported at N $461 mn (-23% MoM), Elan expects Q426 remains a challenging quarter amid softer demand environment and ongoing inventory adjustment. Nevertheless, we think channel inventory is on track to be depleted in the coming months and Q426 is likely to mark the trough for near-term revenue. We forecast Q426E sales to decline 38% QoQ in Q426E but will rebound by 27% QoQ in Q127E on restocking. Into 2027, Elan noted it has won some new projects at top NB brands, while also sees share gain opportunities following its peer's business restructure, as well as ramping low-cost solution to capture market trend. It also see good progress of haptics (2026 sales 5-6x vs 2025) and single layer on-cell (3-4x), and we believe the momentum should continue into 2027.

ADAS and Drone remain key long-term growth drivers

Elan's AI-related revenue reached 14% of sales in Q326 and is expected to further increase in Q426F as AI revenue remains more resilient vs NB-related products. Its ADAS revenue is primarily driven by EV bus now and it thinks the proliferation into logistic vehicles should be the next driver. Its drone-related business is on track to see higher revenue contribution from 2027F as it has penetrated into hunder iger's supply chain, as well as two other customers, supplying both domestic and overseas demand. Elan noted on top of the camera modules, its obstacle avoidance system, which carries much higher ASP of US$800, could start to ramp from Q127F. We forecast its AI-business to see a 45% sales CAGR in 2025-30E, outpacing traditional HMI.

Val ation: Maintain b y with a NT$150 price target

We cut 2026/27/28E EPS to N $6.35/6.94/11.55 from N $8.19/10.82/13.28 on softer NB demand and prolonged inventory adjustment. We lower our P to N $150 (from N $170) using a lower multiple of 15x H227-H128E PE (from 16x 2027E P/E) to factor in overall market valuation contraction. We view current headwinds as cyclical and believe the market underappreciates Elan's AI opportunities and upside from share gain.

Highlights (NT$m) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
Reven es 12,059 12,696 12,326 10,032 10,963 15,300 17,812 19,804
EBIT (UBS) 2,434 3,066 2,982 1,779 2,157 3,908 4,804 5,450
Net earnings (UBS) 2,144 2,736 2,442 1,830 1,996 3,325 4,054 4,578
EPS (UBS, dil ted) (NT$) 7.46 9.52 8.48 6.35 6.94 11.55 14.09 15.91
DPS (net) (NT$) 5.12 7.83 7.07 7.45 6.94 9.51 11.59 13.09
Net (debt) / cash 3,932 3,952 3,023 1,808 1,443 1,775 1,867 2,233
Profitability/val ation 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
EBIT (UBS) margin % 20.2 24.1 24.2 17.7 19.7 25.5 27.0 27.5
ROIC (EBIT) % 67.5 89.7 63.2 29.3 31.0 50.3 55.4 56.9
EV/EBITDA (UBS core) x 10.1 11.1 9.9 13.8 11.9 7.0 5.7 5.0
P/E (UBS, dil ted) x 15.9 16.1 15.6 18.5 16.9 10.2 8.3 7.4
Eq ity FCF (UBS) yield % 9.4 4.3 2.3 2.1 4.1 7.9 9.6 11.8
Dividend yield (net) % 4.3 5.1 5.3 6.3 5.9 8.1 9.9 11.1

Source: Company accounts, LSEG Eikon, UBS estimates. Metrics marked as (UBS) have had analyst adjustments applied. Valuations: based on an average share price that year, (E): based on a share price of N $ 117.50 on 05-Nov-2026

Eq ities

aiwan

Semiconductors

12-month rating B y
12m price target NT$150.00
Prior : NT$170.00
Price (05 Nov 2026) NT$117.50

RIC: 2458. WBBG: 2458

Trading data and key metrics

52-wk range N $189.00-115.50
Market cap. N $33.6b/US$1.02b
Shares o/s 286m (ORD)
Free float 76%
Avg. daily vol me ('000) 1,955
Avg. daily val e (m) N $269.8
Common s/h eq ity (12/26E) N $10.3b
P/BV (12/26E) 3.3x
Net debt to EBITDA (12/26E) NM
EPS (UBS, dil ted) (TWD) EPS (UBS, dil ted) (TWD) - From EPS (UBS, dil ted) (TWD) - To EPS (UBS, dil ted) (TWD) - % ch EPS (UBS, dil ted) (TWD) - Cons.
12/26E 8.19 6.35 -22 9.05
12/27E 10.82 6.94 -36 9.97
12/28E 13.28 11.55 -13 12.07

Jerry S

Analyst jerry.su@ubs.com +886-28-722 7306

Annie Chen

Associate Analyst annie.chen@ubs.com +886-2-8722 7281

Fig re 1: UBS vs. consens s estimates

(NT$m) Q226 - Actual Q326 - Actual Q326 - UBSe prior Q326 - Eikon Q426E - UBSe Q426E - UBSe prior Q426E - Eikon 2025 2026E - Actual 2025 2026E - UBSe 2025 2026E - UBSe prior 2025 2026E - Eikon 2027E - UBSe 2027E - UBSe prior 2027E - Eikon 2028E - UBSe 2028E - UBSe prior 2028E - Eikon
Revenue 3,205 2,221 2,434 2,805 1,382 2,540 3,030 12,326 10,032 11,403 12,282 10,963 14,216 13,719 15,300 17,874 15,641
- QoQ / YoY -0.6% -30.7% -24.1% -12.5% -37.8% 4.4% 8.0% -2.9% -18.6% -7.5% -0.4% 9.3% 24.7% 11.7% 39.6% 18.9% 14.0%
Gross profit 1,519 992 1,104 1,340 620 1,164 1,402 5,996 4,668 5,324 5,797 5,116 6,802 6,336 7,395 8,720 7,343
- Gross margin 47.4% 44.7% 45.3% 47.8% 44.9% 45.8% 46.3% 48.6% 46.5% 46.7% 47.2% 46.7% 47.8% 46.2% 48.3% 48.8% 46.9%
Operating profit 697 296 394 564 7 445 639 2,982 1,779 2,315 2,695 2,157 3,554 3,181 3,908 4,803 3,772
- OP margin 21.7% 13.3% 16.2% 20.1% 0.5% 17.5% 21.1% 24.2% 17.7% 20.3% 21.9% 19.7% 25.0% 23.2% 25.5% 26.9% 24.1%
Non-Op 294 -100 37 36 56 29 20 -132 312 422 402 119 119 127 119 16 131
Pre-tax profit 991 196 432 600 64 473 659 2,850 2,090 2,736 3,097 2,276 3,673 3,308 4,027 4,819 3,903
Tax 146 53 86 118 14 95 151 543 377 491 495 455 735 575 867 964 755
- Tax rate -15% -27% -20% -20% -22% -20% -23% -19% -18% -18% -16% -20% -20% -17% -22% -20% -19%
Net profit 879 168 370 493 78 407 554 2,442 1,830 2,361 2,626 1,996 3,113 2,774 3,325 4,006 3,337
Diluted EPS (NT$) 3.05 0.58 1.29 1.71 0.27 1.41 1.92 8.48 6.35 8.19 9.11 6.94 10.82 9.64 11.55 13.80 11.59

Source: UBS estimates, LSEG

Fig re 2: Elan's ann al P&L

Ticker Shares outstanding (mn) - Year 2025 2458.TWCurrent 286.3 - 2026E Price (NT$) Mkt cap (NT$ mn) - 2027E Price (NT$) Mkt cap (NT$ mn) - 2028E $117.5 $33,643 - 2029E 2030E
Revenues (NT$ mn) $12,326 $10,032 $10,963 $15,300 $17,812 $19,804
YoY Growth (%) -18.6% 9.3% 39.6% 16.4% 11.2%
Gross profit (NT$mn) $5,996 $4,668 $5,116 $7,395 $8,677 $9,670
GM (%) 48.6% 46.5% 46.7% 48.3% 48.7% 48.8%
Operating profit (NT$mn) $2,982 $1,779 $2,157 $3,908 $4,804 $5,450
OPM (%) 24.2% 17.7% 19.7% 25.5% 27.0% 27.5%
Net profit (NT$ mn) $2,442 $1,830 $1,996 $3,325 $4,054 $4,578
EPS (NT$) $8.48 $6.35 $6.94 $11.55 $14.09 $15.91
EPS growth (%) -11% -25.1% 9.3% 66.6% 21.9% 12.9%
P/E (x) 13.9 18.5 16.9 10.2 8.3 7.4
Dividend yield (%) 6.0% 6.3% 5.9% 8.1% 9.9% 11.1%
P/B (x) 3.3 3.3 3.2 2.9 2.7 2.5
ROE (%) 23.7% 17.8% 18.9% 28.8% 32.6% 34.1%

Source: Company data, UBS estimates.

Fig re 3: Elan's ann al and q arterly forecasts

0.4% -3.8% -2.5% -5.8% 3.4% 5.7% -33.0% -51.7% 5.3% -2.9% -18.6% 9.3% 39.6%

50.1% 48.0% 47.2% 49.3% 47.6% 47.4% 44.7% 44.9% 48.9% 48.6% 46.5% 46.7% 48.3%

25.2% 24.5% 23.9% 23.1% 24.1% 21.7% 13.3% 0.5% 24.1% 24.2% 17.7% 19.7% 25.5%

28.4% 26.2% 18.3% 7.2% 19.5% 14.7% 27.3% 22.0% 20.8% 19.0% 18.0% 20.0% 21.5%

-19.7% -52.1% 13.0% 22.0% 28.6% 148.5% -79.1% -89.4% 27.6% -10.7% -25.1% 9.1% 66.6%

Quarters Q125 Q225 Q325 Q425 Q126 Q226 Q326 Q426E
Revenues (NT$ mn) $3,119 $3,032 $3,316 $2,860 $3,225 $3,205 $2,221 $1,382
-- QoQ Growth (%) 2.7% -2.8% 9.4% -13.8% 12.8% -0.6% -30.7% -37.8%
-- YoY Growth (%) 0.4% -3.8% -2.5% -5.8% 3.4% 5.7% -33.0% -51.7%
Gross profit $1,564 $1,457 $1,566 $1,410 $1,537 $1,519 $992 $620
-- Gross Margin (%) 50.1% 48.0% 47.2% 49.3% 47.6% 47.4% 44.7% 44.9%
Operating profit $785 $744 $792 $661 $779 $697 $296 $7
-- OP Margin (%) 25.2% 24.5% 23.9% 23.1% 24.1% 21.7% 13.3% 0.5%
Non-op ($66) ($324) $151 $106 $61 $294 ($100) $56
Pre-tax profit (NT$ mn) $719 $420 $943 $768 $840 $991 $196 $64
Tax $204 $110 $173 $55 $164 $146 $53 $14
-- tax rate (%) 28.4% 26.2% 18.3% 7.2% 19.5% 14.7% 27.3% 22.0%
Net profit (NT$ mn) $548 $354 $804 $736 $705 $879 $168 $78
-- QoQ Growth (%) -9.1% -35.5% 127.4% -8.6% -4.1% 24.7% -80.9% -53.8%
-- YoY Growth (%) -19.7% -52.1% 13.0% 22.0% 28.6% 148.5% -79.1% -89.4%
EPS (NT$) $1.90 $1.23 $2.79 $2.57 $2.43 $3.05 $0.58 $0.27
2024 2025 2026E 2027E 2028E
$12,696 $12,326 $10,032 $10,963 $15,300
5.3% $6,204 -2.9% $5,996 -18.6% $4,668 9.3% 39.6%
$5,116 $7,395
48.9% 48.6% 46.5% 46.7% 48.3%
$3,066 $2,982 $1,779 $2,157 $3,908
24.1% 24.2% 17.7% 19.7% 25.5%
$207 ($132) $312 $119 $119
$3,273 $2,850 $2,090 $2,276 $4,027
$680 $543 $377 $455 $867
20.8% 19.0% 18.0% 20.0% 21.5%
$2,736 $2,442 $1,830 $1,996 $3,325
27.6% -10.7% -25.1% 9.1% 66.6%
$9.52 $8.48 $6.35 $6.94 $11.55

Source: Company data, UBS estimates

Fig re 4: Elan trades near its historical P/E m ltiple

Source: LSEG

Fig re 5: Elan's FINI ownership recovering from near-term tro gh

Source: EJ

Forecast ret rns

Forecast price appreciation 27.7%
Forecast dividend yield 6.3%
Forecast stock return 34.0%
Market return assumption 6.3%
Forecast e cess return 27.7%

Company Description

Elan Microelectronics is a aiwan-based fabless IC design house specialising in humanmachine interface including touchscreen controllers, touchpad modules, pointing stick modules and fingerprint sensors, specifically for notebook PCs. It started with microcontrollers (MCUs) for PC peripherals and consumer electronics upon establishment in 1994, and further expanded the reach into notebook PC input devices through the acquisition of a related subsidiary under KOA Corporation in 2003.

Val ation Method and Risk Statement

Our price target is based on a target PE multiple.

Fabless integrated circuit (IC) design houses face a variety of uncertainties, including rapidly changing technology, end-market demand, competition, employee turnover and foundry wafer costs. hey are also vulnerable to legal disputes over intellectual property rights.

For Elan, we believe key risks include: 1) PC and NB demand dynamics, with any slowdown in these end-markets directly impacting Elan's growth and also its new product roll-outs; 2) a longer-than-expected product qualification cycle or slower-than-expected product adoption among clients; 3) fiercer-than-expected price competition from global and Asian peers negatively impacting growth and gross margin; and 5) faster-than-expected foundry and assembly cost increases negatively impacting gross margin.

Q antitative Research Review

UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. he views for this month can be found below. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For previous responses please make reference to (i) previous UBS Global Research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at https://neo.ubs.com/quantitative, or contact your UBS sales representative for access to the report or the Quantitative Research eam on ubs-quant-answers@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research eam on the email above.

Elan Microelectronics

Q estion Response
1. Is the industry structure facing the firm likely to improve or deteriorate over the ne t si months? Rate on a scale of 1-5 (1 = getting worse, 3 = no change, 5 = getting better, N/A = no view) 2
2. Is the regulatory/government environment facing the firm likely to improve or deteriorate over the ne t si months? Rate on a scale of 1-5 (1 = getting tougher 3 = no change, 5 = getting better, N/A = no view) 3
3. Over the last 3-6 months in broad terms have things been improving/no change/getting worse for this stock? Rate on a scale of 1-5 (1 = getting a lot worse, 3 = not much change, 5 = getting a lot better, N/A = no view) 3
4. Relative to the current CONSENSUS EPS forecast, is the ne t company EPS update likely to lead to: (1 = negative surprise vs consensus, 3 = in-line with consensus, 5 = positive surprise vs consensus e pectations, N/A = no view) 3
5. What's driving the difference?
6. Relative to YOUR current earnings forecast, is there relatively greater risk at the ne t earnings result of:(1 = downside skew risk to earnings, 3 = equal upside or downside risk to earnings, 5 = upside skew risk to earnings, N/A = no view) 3
7. What's driving the difference?
8. Is there an upcoming catalyst for the company over the ne t three months? No Catalyst
9. Is there an actual or appro imate date for the catalyst?
10. Is the catalyst date an actual or appro imate date?
11. What is the catalyst?

Req ired Disclos res

his document has been prepared by UBS Securities Pte. Ltd., aipei Branch, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

For information on how UBS manages conflicts and maintains the independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and terms and conditions for certain third party data used in research report, please visit https://www.ubs.com/disclosures. Unless otherwise indicated, information and data in this report are based on company disclosures including annual, interim and quarterly reports and other company announcements. Figures in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available on request. UBS Securities Co. Limited is licensed by the China Securities Regulatory Commission to conduct securities investment consultancy businesses. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. his recommendation was finalized on: 05 November 2026 11:55 AM GM . UBS has designated certain UBS Global Research department members as Derivatives Research Analysts where they publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient on which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. Q antitative Research Review: UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of a number of short term factors occurring, in a product known as the 'Quantitative Research Review'. Views in this assessment on a particular stock reflect only those short term factors and a timeframe different to the 12-month timeframe reflected in any equity rating set out in this document. For the latest responses, please see the Quantitative Research Review Addendum at the back of this document, where applicable. For previous responses, please refer to: (i) previous UBS Global Research reports and (ii) where no applicable research report was published that month, the Quantitative Research Review at https://neo.ubs.com/quantitative, or contact your UBS sales representative for access to the report or the Quantitative Research eam at ubs-quant-answers@ubs.com. A consolidated report containing all responses is also available; for details and pricing, please contact your UBS sales representative or the Quantitative Research team at the above email.